Baird lowered the firm’s price target on Applied Therapeutics to $14 from $18 and keeps an Outperform rating on the shares. The analyst said the separation between treatment and placebo over time on the primary, originally designed primary endpoint and multiple important subgroups and secondaries could set up an interesting registrational pathway at FDA.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLT:
- Applied Therapeutics sells 9.74M shares at 94.6c in private placement
- Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
- Applied announces benefits of govorestat in ACTION-Galactosemia kids trial
- Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
- Applied Therapeutics price target lowered to $5 from $23 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue